Cerebral Amyloid Angiopathy (CAA)

Cerebral amyloid angiopathy, or CAA, is a disease of the small and medium blood vessels on the surface and in the outer parts of the brain. In CAA, a protein called amyloid-β slowly collects in the wall of these arteries, arterioles, and sometimes capillaries. The protein makes the vessel wall weak and stiff. Over time, this can lead to tiny leaks, small spots of old blood (called microbleeds), or larger bleeds in the outer (lobar) parts of the brain. Some people develop short, spreading neurological symptoms (called “amyloid spells”), seizures, headaches, or memory and thinking problems. CAA is most common with aging and often occurs together with Alzheimer-type brain changes. Diagnosis usually relies on brain imaging patterns and clinical rules (Boston criteria), and a brain biopsy is rarely needed. NCBIPMC

CAA is a brain blood-vessel disease. A protein called amyloid-β (Aβ) slowly builds up in the walls of small and medium arteries on the surface and in the outer parts of the brain. These vessels become fragile and can leak blood. This can cause lobar intracerebral hemorrhage (bleeding in the outer brain), tiny microbleeds, superficial siderosis (old blood staining), brief “amyloid spells” (short-lasting tingling or weakness), seizures, and thinking problems. Doctors diagnose CAA during life with Boston criteria v2.0, which combine MRI signs with clinical features; a brain biopsy proves it, but biopsy is rarely needed. There is no approved cure yet; care focuses on bleeding prevention, blood-pressure control, seizure care, and (in a special inflammatory variant) short-term immune suppression. PMCAmerican Academy of NeurologyMDPI

---

Other names

CAA is also called congophilic angiopathy, amyloid angiopathy, cerebral β-amyloid angiopathy, and, when the immune system reacts to vascular amyloid, CAA-related inflammation (CAA-ri) or amyloid-β–related angiitis (ABRA). “Congophilic” refers to the way amyloid in blood vessel walls stains with Congo-red dye under the microscope. CAA-ri and ABRA are inflammatory variants that usually cause subacute headaches, confusion, seizures, and MRI swelling, and they often respond to steroids and other immunotherapy. The non-inflammatory (typical) form causes lobar hemorrhage, cortical superficial siderosis (old blood lining the cortex), and numerous lobar microbleeds. PMC+1

---

Types

1. Sporadic CAA (age-related). The most common form. It appears in older adults without a single inherited gene mutation. It often coexists with Alzheimer pathology and shows lobar microbleeds and superficial siderosis on MRI. NCBI

2. Hereditary (familial) CAA. Rare inherited forms caused by mutations, most often in the APP gene (for example, “Dutch,” “Iowa,” “Arctic,” “Italian,” “Piedmont” variants) or, in another amyloid disease, the cystatin-C mutation (Icelandic type). These forms usually present earlier in life and can cause recurrent hemorrhage. Down syndrome (extra APP copies) can also lead to early amyloid deposition, including in vessels. NCBI

3. CAA-related inflammation (CAA-ri). An autoimmune reaction to vascular amyloid that produces brain swelling on MRI, headaches, subacute cognitive decline, and seizures. It is often responsive to steroids and other immunosuppressants. ABRA is the vasculitic end of this spectrum, with granulomatous vessel wall inflammation. PMC+1

4. Iatrogenic (acquired) CAA. Very rare; linked to exposure to cadaveric pituitary growth hormone or cadaveric dural grafts in childhood neurosurgery. Decades later, patients can develop vascular amyloid and lobar hemorrhage. NatureSurgical Neurology International

5. Pathological subtypes by vessel involvement. Some authors describe “capillary CAA (type 1)” when capillaries are involved and “non-capillary CAA (type 2)” when only arteries/arterioles are affected. This distinction can track with different clinical and imaging patterns. PMC

---

Causes

Important note: in most people CAA is not caused by one single event. It develops over many years because amyloid-β is not cleared well from the brain’s perivascular drainage pathways. Below are well-described drivers, risks, and special situations that lead to or accelerate vascular amyloid build-up and its complications.

1. Aging. With age, arteries stiffen and perivascular clearance slows, so amyloid-β collects in vessel walls. NCBI

2. Impaired perivascular drainage (“glymphatic”) of amyloid-β. Failure of these clearance routes favors amyloid deposition around vessels. NCBI

3. APOE ε4 genotype. Strongly linked to amyloid deposition in brain and vessels; increases risk of CAA pathology. PMC

4. APOE ε2 genotype. Tied to fragile, vasculopathic vessel changes and higher risk of lobar hemorrhage in CAA. BioMed Central

5. Alzheimer disease co-pathology. Parenchymal amyloid and vascular amyloid often coexist and can feed each other. NCBI

6. APP gene mutations (hereditary CAA). “Dutch,” “Iowa,” “Arctic,” “Italian,” “Piedmont” variants change the amyloid peptide and promote vascular build-up. NCBI

7. APP gene over-expression (Down syndrome). Extra APP copies speed amyloid production, including in vessels. NCBI

8. Cystatin-C (Icelandic) mutation. Produces amyloid that targets vessel walls early in life. NCBI

9. Iatrogenic exposure to amyloid seeds. Cadaveric growth hormone or dural grafts can transmit amyloid-β “seeds,” with CAA decades later. NatureSurgical Neurology International

10. Vascular smooth muscle cell loss and wall degeneration. Amyloid injures the muscular layer, weakening vessels. NCBI

11. Cortical superficial siderosis (marker of prior bleeding). Recurrent small bleeds reflect fragile vessels and raise future bleed risk. PMC

12. Multiple lobar microbleeds. A sign of widespread vascular amyloid and bleeding tendency. PMC

13. CAA-related inflammation. Autoimmune attack on amyloid-laden vessels makes leakage and edema more likely. PMC

14. Arterial stiffness and small-vessel disease. Reduced pulsation impairs perivascular clearance of amyloid. j-stroke.org

15. Prior lobar intracerebral hemorrhage. Indicates advanced CAA; the underlying process promotes future bleeds. j-stroke.org

16. Antithrombotic exposure (context factor). Blood thinners and some antiplatelets do not cause CAA but can unmask bleeding risk in CAA-fragile vessels (clinical management nuance). j-stroke.org

17. Traumatic cortical contusions in the elderly. Not a primary cause, but trauma can bleed more readily in amyloid-weakened cortex. NCBI

18. Sleep and clearance disruption (concept). Poor sleep and reduced arterial pulsatility may slow amyloid removal over time. j-stroke.org

19. ApoE-related lipid transport changes. ApoE isoforms alter amyloid aggregation/clearance along vessel walls. ScienceDirect

20. Coexisting hypertension (context). Hypertension mainly causes deep bleeds, but if present with CAA it may add to overall hemorrhage risk even though it is not the primary driver of vascular amyloid. j-stroke.org

---

Symptoms and signs

1. Sudden weakness or numbness on one side. A lobar brain bleed can damage the nearby motor or sensory cortex, causing one-sided symptoms.

2. Speech trouble. If bleeding or irritation affects language areas, the person may have trouble speaking or understanding words.

3. Vision loss or blind spots. Occipital lobe involvement can cause sudden visual field gaps or “patchy” vision.

4. Seizures. Irritable cortex near amyloid deposits or blood products can trigger focal or generalized seizures.

5. Transient focal neurological episodes (“amyloid spells”). Brief, spreading tingling, numbness, or weakness that moves across a hand, face, or limb over minutes; often due to superficial siderosis irritating the cortex.

6. Headache. Large bleeds and CAA-ri can cause pressure-type headaches; new daily headache in an older adult deserves attention.

7. Confusion or fluctuating alertness. Acute hemorrhage or CAA-ri can disturb brain networks and cause waxing–waning confusion.

8. Memory and thinking problems. Chronic small bleeds, microinfarcts, and white-matter injury can lead to slow, executive-type cognitive decline.

9. Gait imbalance and falls. White-matter damage and cortical injury can affect coordination and balance.

10. Nausea and vomiting. Raised pressure with a large lobar bleed can provoke vomiting.

11. Neglect or inattention to one side. Parietal lobe involvement may cause the person to ignore the left or right side of space.

12. Numbness or abnormal sensations. Irritation of sensory cortex by superficial siderosis can produce tingling or “pins and needles.”

13. Mood or personality change. Frontal lobe injury can lead to apathy, depression, or irritability.

14. Drowsiness or coma in severe bleeds. A large hemorrhage can depress consciousness.

15. Recurring mild strokes or microinfarcts (often silent). Not felt at the time but add up to cognitive and gait problems later.

(These patterns are well described in CAA and CAA-ri; the “amyloid spells,” lobar bleeds, cortical superficial siderosis, and lobar microbleeds are especially characteristic.) PMC+2PMC+2

---

Diagnostic tests

A) Physical examination

1. General neurological examination. The clinician checks strength, sensation, reflexes, coordination, and cranial nerves. In CAA, the exam may show focal deficits that match a lobar hemorrhage or seizure after-effects. It also helps rule out stroke from other causes. NCBI

2. Cognitive screening (MoCA or MMSE at bedside). Short tests of attention, memory, language, visuospatial skills, and executive function. They track whether CAA is causing thinking changes over time.

3. Gait and balance assessment. Simple walking tasks, tandem gait, and turning can reveal white-matter-related gait slowing and instability that are common in small-vessel diseases like CAA.

4. Vital signs and cardiovascular check. Blood pressure, heart rhythm, and general medical status guide safety and help identify other contributors to bleeding risk.

B) Manual bedside tests

5. Pronator drift. With both arms outstretched, subtle downward drift of a hand suggests contralateral motor cortex involvement after a lobar bleed.

6. Confrontation visual fields. The examiner maps blind spots; occipital or parietal hemorrhage may cause homonymous field loss.

7. Neglect screening (line bisection or clock drawing). Right parietal involvement can cause the person to ignore the left side of space or crowd numbers on one side of a clock.

8. Rapid alternating movements and coordination tasks. Detect subtle cortical or white-matter injury affecting fine motor control.

9. Romberg and postural tests. Reveal proprioceptive or balance impairment related to widespread small-vessel damage.

C) Laboratory and pathological tests

10. Complete blood count and platelets with basic chemistries. Not diagnostic of CAA but essential to rule out anemia, infection, or low platelets that might explain or worsen bleeding. Coagulation studies (PT/INR, aPTT) check for treatment-related bleeding tendencies. NCBI

11. Inflammation markers (ESR/CRP) when CAA-ri is suspected. Elevations support an inflammatory picture and can guide the decision to treat with steroids (after imaging). PMC

12. Cerebrospinal fluid (CSF) analysis in selected cases. In CAA-ri, CSF may show mild inflammation (e.g., elevated protein) and sometimes anti-Aβ autoantibodies in research settings; it also helps exclude infection. PMC

13. Brain or meningeal biopsy (rare, targeted). The only way to prove CAA pathologically is to show amyloid in vessel walls (Congo-red–positive) and, in ABRA, inflammatory destruction. Biopsy is reserved for unclear or steroid-refractory cases. NCBIPMC

D) Electrodiagnostic tests

14. Routine EEG. Looks for seizure activity or irritability in cortex affected by microbleeds, superficial siderosis, or inflammation. It explains episodes that mimic strokes. PMC

15. Prolonged or ambulatory EEG when spells are infrequent. Increases the chance of capturing a seizure correlate during brief sensory or motor episodes.

E) Imaging tests

16. Non-contrast CT head (first-line in emergencies). Quickly shows acute hemorrhage. In CAA, bleeds favor the lobar (outer) brain rather than deep structures typical of long-standing hypertension. j-stroke.org

17. MRI with T2 (GRE) or susceptibility-weighted imaging (SWI).* The key test to detect multiple lobar microbleeds and cortical superficial siderosis—hallmark signs of CAA. These features are central to the modern (Boston v2.0) diagnostic rules. PMC+1

18. MRI FLAIR (edema and white-matter changes). Shows asymmetric cortical–subcortical edema in CAA-ri and the background white-matter hyperintensities seen in small-vessel disease. PMC

19. Amyloid-PET (e.g., PiB PET) in selected centers. Detects cortical amyloid burden; it supports the diagnosis when MRI suggests CAA, although it does not by itself distinguish vascular from parenchymal amyloid. NCBI

20. CTA/MRA or catheter angiography (when needed to rule out other causes). These tests usually look normal in CAA but help exclude aneurysm or AVM in atypical cases (e.g., subarachnoid hemorrhage pattern or unusual patient profile). NCBI

Boston criteria v2.0. Doctors combine age, presentation (lobar hemorrhage, cognitive issues, or amyloid spells), and MRI markers (lobar microbleeds, superficial siderosis, white-matter/perivascular signs) to classify probable CAA without biopsy. The v2.0 rules improved accuracy compared with previous versions. PMCPubMed

Non-Pharmacological Treatments

Physiotherapy & Rehabilitation

1. Individualized gait & balance training
   Purpose: reduce falls and injury. Mechanism: task-specific practice, strengthening ankles/hips, vestibular drills. Benefits: steadier walking, fewer slips, more confidence.

2. Strength training (2–3×/week)
   Purpose: build leg and core strength for stability. Mechanism: progressive resistance (bodyweight, bands). Benefits: better transfers, stair safety, independence.

3. Flexibility & posture work
   Purpose: keep joints mobile, reduce stiffness after hemorrhage. Mechanism: daily gentle stretches, thoracic extension. Benefits: smoother gait, less pain, easier self-care.

4. Task-oriented mobility practice
   Purpose: restore daily function. Mechanism: repetitive practice of sit-to-stand, bed mobility. Benefits: faster ADL recovery, less caregiver load.

5. Cueing & dual-task training
   Purpose: prepare for real-life walking with distractions. Mechanism: combine walking with simple cognitive tasks. Benefits: fewer missteps in crowds or busy rooms.

6. Assistive device assessment
   Purpose: choose cane/walker correctly. Mechanism: PT measures height, observes gait. Benefits: safer walking, fewer falls.

7. Home safety evaluation
   Purpose: remove hazards. Mechanism: PT/OT suggests grab bars, lighting, non-slip mats, decluttering. Benefits: fall risk drops immediately.

8. Vestibular therapy (if dizzy)
   Purpose: reduce imbalance. Mechanism: gaze stabilization, habituation exercises. Benefits: steadier head turns, fewer falls.

9. Functional electrical stimulation (selected deficits)
   Purpose: help weak dorsiflexors or quads activate. Mechanism: timed stimulation during gait. Benefits: better foot clearance, stronger steps.

10. Constraint-induced/forced-use strategies (mild hemiparesis)
    Purpose: overcome “non-use.” Mechanism: limit good side, intensively train weaker side. Benefits: improved limb use in daily life.

11. Occupational therapy for ADLs & vision
    Purpose: adapt to field cuts or neglect. Mechanism: scanning training, prism strategies, one-hand techniques. Benefits: safer cooking, dressing, reading.

12. Speech-language therapy
    Purpose: language and cognitive-communication. Mechanism: naming, fluency, compensatory tools. Benefits: clearer communication, reduced frustration.

13. Cognitive rehabilitation
    Purpose: attention, memory, executive skills. Mechanism: graded tasks, notebooks, phone reminders. Benefits: better medication management and appointments.

14. Spasticity & tone management (non-drug)
    Purpose: reduce stiffness. Mechanism: prolonged stretch, splints, positioning. Benefits: easier hygiene, fewer contractures.

15. Endurance training (walk or cycle most days)
    Purpose: vascular health and brain perfusion. Mechanism: moderate aerobic sessions, BP friendly. Benefits: stamina, mood, BP control.

Mind-Body, “Gene,” & Educational Therapies

16. Blood-pressure self-management program
    Purpose: keep long-term BP ≤130/80 when appropriate. Mechanism: home cuff, logs, coaching, salt goals. Benefits: lower re-bleed risk. AHJournals

17. Sleep optimization & apnea care
    Purpose: improve amyloid clearance and cognition. Mechanism: regular schedule, CPAP if OSA, dark quiet room. Benefits: clearer thinking, steadier daytime BP.

18. Stress reduction (breathing, mindfulness)
    Purpose: blunt BP surges. Mechanism: slow breathing, brief daily practice. Benefits: calmer mood, steadier BP.

19. Mediterranean/DASH-style eating pattern
    Purpose: vascular health. Mechanism: fruits/veg, whole grains, legumes, fish, olive oil; limit salt and processed foods. Benefits: better BP, metabolic profile. AHJournals

20. Alcohol moderation & smoking cessation
    Purpose: reduce bleeding and small-vessel injury. Mechanism: counseling, NRT, supports. Benefits: fewer bleeds, better rehab results.

21. Medication safety education
    Purpose: minimize bleeding medicines. Mechanism: avoid unnecessary anticoagulants/dual antiplatelets; single low-dose antiplatelet only if strong ischemic indication. Benefits: lower hemorrhage risk. (Risk-benefit per guidelines; individualized.) AHJournals

22. Seizure first-aid training for family
    Purpose: respond safely. Mechanism: positioning, timing, when to call EMS. Benefits: safer home management.

23. Caregiver skills & respite planning
    Purpose: sustain home care. Mechanism: training, community resources. Benefits: fewer hospital readmissions.

24. Advance care planning
    Purpose: align care with values. Mechanism: simple forms, goals-of-care talks. Benefits: less crisis-driven decision-making.

25. Genetics & risk education (not “gene therapy”)
    Purpose: explain APOE/hereditary forms. Mechanism: counseling on what results mean and do not mean. Benefits: realistic expectations; avoids misinformation. Note: There is no approved gene therapy for CAA at this time.

---

Drug Treatments

(Doses are typical adult ranges; adjust for age, kidney/liver function, drug interactions. In CAA, the most proven “drug” strategy is blood-pressure control and careful seizure management; CAA-ri is treated with short-term immunosuppression. Antithrombotics are generally minimized unless there is a compelling reason.)

1. Amlodipine (calcium-channel blocker) – 5–10 mg once daily. Purpose: long-term BP control. Mechanism: vasodilation of resistance vessels. Benefit: lowers re-bleed risk; Side effects: edema, flushing. Target long-term BP often ≤130/80 when safe. AHJournals

2. Lisinopril (ACE inhibitor) – 10–40 mg daily. Purpose: BP control. Mechanism: RAAS blockade, endothelial benefit. Side effects: cough, high potassium, rare angioedema. AHJournals

3. Losartan (ARB) – 50–100 mg daily. Purpose: alternative to ACEi. Mechanism: AT1 receptor blockade. Side effects: dizziness, high potassium. AHJournals

4. Indapamide or Hydrochlorothiazide (thiazide diuretic) – Indapamide 1.25–2.5 mg; HCTZ 12.5–25 mg daily. Purpose: add-on BP control. Mechanism: natriuresis; vascular remodeling. Side effects: low sodium/potassium, gout. AHJournals

5. Nicardipine IV (acute ICH BP control) – continuous infusion titrated in ICU. Purpose: safely lower very high BP in acute bleed. Side effects: hypotension, headache. (Acute management per guidelines.) AHJournalswww.heart.org

6. Labetalol IV (acute ICH spikes) – IV bolus/infusion as needed. Purpose: rapid BP control. Side effects: bradycardia, bronchospasm. AHJournals

7. Levetiracetam (anti-seizure) – 500–1500 mg twice daily. Purpose: treat or prevent recurrent post-ICH seizures. Mechanism: modulates synaptic release. Side effects: somnolence, mood change.

8. Lamotrigine (anti-seizure) – slow titration to 100–200 mg/day. Purpose: focal seizures; Side effects: rash (titrate slowly).

9. Mannitol or Hypertonic saline (acute edema) – ICU use. Purpose: reduce raised intracranial pressure after large hemorrhage. Mechanism: osmotic shift; Risks: electrolyte shifts. AHJournals

10. Reversal of warfarin (PCC + vitamin K) – PCC ~50 IU/kg + 10 mg IV vitamin K. Purpose: quickly reverse anticoagulation in ICH. Benefit: limits hematoma expansion; Risks: thrombosis. AHJournals

11. Idarucizumab (for dabigatran) – 5 g IV. Purpose: rapid DOAC reversal in ICH. Risks: rebound clot risk. AHJournals

12. Andexanet alfa (for apixaban/rivaroxaban) – per label dosing. Purpose: DOAC reversal in ICH. Risks: thrombosis, infusion reactions. AHJournals

13. High-dose corticosteroids for CAA-ri – e.g., methylprednisolone 500–1000 mg/day for 3–5 days, then slow oral taper. Purpose: quell vessel wall inflammation. Mechanism: broad immune suppression. Side effects: glucose rise, mood change, infection. Evidence shows frequent clinical and radiologic response. PMCJAMA NetworkBioMed Central

14. Cyclophosphamide (refractory CAA-ri) – specialist use (e.g., monthly IV). Purpose: steroid-refractory cases. Side effects: infection, cytopenias, cystitis; used cautiously. JAMA Networkjns-journal.com

15. Rituximab (selected refractory CAA-ri) – specialist use. Purpose: reduce relapses when steroids alone insufficient. Side effects: infusion reactions, infection risk. JAMA Network

Important: Anticoagulants and dual antiplatelets are generally avoided in probable CAA because they raise bleeding risk. If stroke prevention for atrial fibrillation is essential, teams may consider left atrial appendage occlusion as a non-pharmacologic alternative to long-term anticoagulation (see “Surgeries/Procedures” below). Decisions are individualized. AHJournalssvn.bmj.com

---

Dietary / Molecular Supplements

None of these treats vessel amyloid. Discuss with a clinician to avoid interactions and bleeding risk.

1. Omega-3 fatty acids (fish oil; diet first) – may support vascular health and triglycerides; typical 1 g/day EPA+DHA if supplementing; watch platelet effects.

2. Vitamin D – correct deficiency (e.g., 800–2000 IU/day) for bone/falls; monitor levels.

3. B-complex (B12, folate, B6) – correct deficiencies to lower homocysteine and support cognition; dose per labs.

4. Magnesium – supports BP and sleep; avoid excess in CKD.

5. Potassium (dietary) – fruits/veg/DASH; supplement only if safe with kidneys and meds.

6. Cocoa flavanols (dietary cocoa) – may aid endothelial function; avoid sugar-heavy products.

7. Curcumin/turmeric (dietary use) – experimental amyloid interactions; caution with antiplatelet effect.

8. Resveratrol (dietary grapes/berries) – antioxidant; supplement evidence limited.

9. Coenzyme Q10 – general mitochondrial support; evidence mixed.

10. Probiotics/fiber – gut-vascular links; emphasize whole foods.

(These are general brain- and vessel-health supports; strong CAA-specific evidence is lacking. Primary prevention remains BP control and fall avoidance, per guidelines.) AHJournals

---

Immunity booster / Regenerative / Stem-cell” Drugs

There are no approved immunity-booster, regenerative, or stem-cell drugs for CAA. Experimental strategies, including anti-amyloid monoclonal antibodies developed for Alzheimer’s disease, are not approved for CAA and may increase microbleeds or ARIA in people with underlying vessel amyloid. If you are exploring research options, discuss clinical trials with a stroke specialist. For now, the safe, evidence-based “disease-modifying” actions are stringent vascular risk control and careful avoidance of bleeding triggers. AHJournals

---

Surgeries / Procedures

1. Minimally invasive or open hematoma evacuation
   What: remove a large lobar clot. Why: relieve pressure, improve outcomes in selected patients with accessible lobar ICH and clinical decline. Decision is case-by-case. AHJournals

2. Decompressive craniectomy (selected malignant swelling)
   What: temporarily remove part of skull to control dangerous pressure. Why: life-saving measure in severe mass effect. AHJournals

3. External ventricular drain (EVD)
   What: drain CSF to treat acute hydrocephalus/pressure after hemorrhage extending to ventricles. Why: protect brain and allow monitoring. AHJournals

4. Left atrial appendage occlusion (LAAO)
   What: catheter device that seals the heart’s LAA in atrial fibrillation. Why: offers stroke prevention without lifelong anticoagulation in people at very high ICH risk (e.g., probable CAA). Post-procedure antithrombotic regimens vary and are individualized. svn.bmj.comAmerican College of CardiologyPubMed

5. Stereotactic brain biopsy (rare)
   What: small tissue sample. Why: only when diagnosis is uncertain (e.g., to confirm CAA-related inflammation) and results would change treatment. PMC

---

Prevention Tips

1. Keep BP ≤130/80 if your doctor agrees; check at home. 2) Review medicines for blood thinners and NSAIDs; avoid unnecessary agents. 3) Use single antiplatelet only when benefit clearly outweighs bleed risk. 4) Don’t smoke; avoid heavy alcohol. 5) Walk most days and do simple strength and balance work. 6) Make the home safe (lights, rails, no loose rugs). 7) Sleep 7–8 hours; treat apnea. 8) Eat Mediterranean/DASH style with less salt. 9) Control diabetes, cholesterol, and kidney disease with your team. 10) Get vision/hearing checked to cut fall risk. AHJournals

---

When to See a Doctor

• Immediately (emergency): sudden weakness/numbness on one side, new trouble speaking or understanding, sudden severe headache, new seizures, sudden vision loss, sudden confusion.

• Soon (urgent clinic): new or worsening “spreading tingling” spells, new gait instability or falls, persistent headaches or cognitive decline, medication side-effects, blood pressure repeatedly above target.

• Routine follow-up: medication checks every 3–6 months, MRI review when indicated, caregiver support and rehab progress review.

---

What to Eat and What to Avoid

• Eat more: vegetables, fruits, beans, lentils, nuts, seeds, whole grains, fish 2×/week, fermented dairy or yogurt, olive oil instead of butter.

• Limit: salt (aim <5–6 g/day of salt), processed meats, refined carbs and sugars, deep-fried/ultra-processed foods.

• Drink: mostly water; tea/coffee in moderation; keep alcohol low or none.

• Habits: regular meals, watch portions, read labels for sodium, cook at home more often. (Matches BP-friendly Mediterranean/DASH patterns.) AHJournals

Frequently Asked Questions

1. Can CAA be cured?
   Not yet. Care reduces bleeding risk and disability. Clinical trials are ongoing.

2. How is CAA diagnosed without biopsy?
   By Boston criteria v2.0, which rely on MRI patterns (lobar microbleeds, cortical superficial siderosis) and clinical context. PMC

3. Is CAA the same as Alzheimer’s?
   No. They share amyloid biology, but CAA targets vessel walls and bleeding risk; Alzheimer’s targets neurons and causes dementia. They often coexist. MDPI

4. What raises re-bleed risk the most?
   Uncontrolled blood pressure and medicines that thin blood (anticoagulants; dual antiplatelets). Decisions are individualized. AHJournals

5. Should people with CAA ever take aspirin?
   Sometimes, if there is a strong ischemic indication and after careful risk discussion; many will avoid it. AHJournals

6. What if I have atrial fibrillation?
   Teams may consider LAA occlusion to avoid lifelong anticoagulation if bleeding risk is very high. svn.bmj.com

7. What is CAA-related inflammation?
   An immune reaction to vessel amyloid causing subacute headaches, confusion, and MRI white-matter swelling; steroids often help. PMC

8. Do “amyloid-clearing” Alzheimer’s antibodies help CAA?
   They are not approved for CAA and can increase ARIA/microbleeds in people with vessel amyloid. Not recommended outside trials.

9. Will exercise cause a bleed?
   Typical moderate exercise lowers BP and is helpful. Avoid contact sports and high-fall-risk activities without supervision.

10. Can diet reverse amyloid in vessels?
    No diet removes amyloid, but Mediterranean/DASH eating supports vessels and BP.

11. Are supplements required?
    Only to correct deficiencies or with clinician approval; whole-food diet first.

12. How often should I have MRI?
    Timing is individualized (e.g., after new symptoms or to monitor CAA-ri response).

13. What home BP monitor should I use?
    Use a validated upper-arm cuff; measure twice daily for 1–2 weeks when adjusting meds.

14. Can I fly?
    Usually yes after stabilization; discuss timing after any recent hemorrhage.

15. What’s the long-term outlook?
    It varies. Many live independently with good BP control and careful medication choices; others have recurrent bleeds or cognitive decline. Early, steady prevention matters.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 08, 2025.